物质信息
ID:346966
名称和标识
IUPAC标准名
3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]pyridin-2-amine
IUPAC传统名
crizotinib
别名
PF-02341066(R)-3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylaminePF 2341066PF02341066XalkoriCrizotinib
化合物性质
理化性质
外观
white to tan powder
产品相关信息
纯度
≥98% (HPLC)
Empirical Formula (Hill Notation)
C21H22Cl2FN5O
安全信息
保存温度
room temp
MSDS下载
描述信息
Legal Information
Sold for research purposes under agreement from Pfizer Inc.
Biochem/physiol Actions
Crizotinib (PF-02341066) is an ATP-competitive inhibitor of the receptor tyrosine kinases (RTKs) c-Met (hepatocyte growth factor receptor) and anaplastic lymphoma kinase (ALK). It is a highly specific inhibitor of c-Met and ALK among > 120 different RTKs surveyed. Crizotinib was recently approved for treatment of a subtype of nonsmall-cell lung cancer (NSCLC) with ALK fusion mutations.
Sold for research purposes under agreement from Pfizer Inc.
Biochem/physiol Actions
Crizotinib (PF-02341066) is an ATP-competitive inhibitor of the receptor tyrosine kinases (RTKs) c-Met (hepatocyte growth factor receptor) and anaplastic lymphoma kinase (ALK). It is a highly specific inhibitor of c-Met and ALK among > 120 different RTKs surveyed. Crizotinib was recently approved for treatment of a subtype of nonsmall-cell lung cancer (NSCLC) with ALK fusion mutations.
分子图谱
暂无数据
点击上传数据
参考文献
暂无数据
点击上传数据